Explore the possibilities
Get to Know Your Peptide Options
Different peptides have different purposes, evidence, risks, and regulatory status. These descriptions are a starting point for a clinical conversation. Recommendations depend on your individual evaluation and the specific medication being considered.
01 / PEPTIDE OPTIONS
PT-141 / Bremelanotide
Questions about low sexual desire deserve a thoughtful conversation. PT-141, also called bremelanotide, acts on melanocortin receptors. The FDA-approved product Vyleesi treats acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women when low desire causes distress and is not explained by another condition, medication, or relationship difficulty.
Important considerations
Vyleesi is not indicated for HSDD in men or postmenopausal women, or to enhance sexual performance. It must not be used with uncontrolled high blood pressure or known cardiovascular disease. Potential effects include nausea, temporary blood-pressure increases, flushing, headache, and skin darkening. Compounded PT-141 is not FDA-approved and does not share Vyleesi’s product approval. Discuss the exact formulation, other medicines, pregnancy considerations, and suitability with your clinician.
02 / PEPTIDE OPTIONS
BPC-157
BPC-157 is an investigational peptide discussed in research on tissue injury and gastrointestinal conditions. Human evidence is limited, and its safety and effectiveness for these uses have not been established. If BPC-157 is on your mind, a consultation can help you examine the evidence, uncertainties, and other approaches to your concern.
Important considerations
BPC-157 is not an FDA-approved medication. FDA has raised concerns about immune reactions, peptide impurities, and insufficient safety information. Claims of faster healing, injury recovery, or treatment of digestive conditions should not be assumed from laboratory or animal studies.
03 / PEPTIDE OPTIONS
CJC-1295 / Ipamorelin
CJC-1295 and ipamorelin are investigational peptides studied in relation to growth-hormone signaling. They are sometimes combined, but the exact CJC form and the evidence for the specific combination matter. A clinical review can help explain how these compounds differ and why hormone-related concerns need individual evaluation.
Important considerations
This combination is not FDA-approved. Evidence does not establish it as a treatment for healthy aging, better sleep, body composition, or exercise recovery. FDA has identified safety concerns with these substances, including reported increases in heart rate and blood-vessel dilation with CJC-1295, along with uncertainties about injectable ipamorelin safety.
04 / PEPTIDE OPTIONS
KLOW
KLOW is a peptide blend reviewed during consultation. Combining peptides creates a formulation that needs its own careful review. Evidence about an individual ingredient does not establish the safety or effectiveness of the blend. Your clinician can explain the exact formulation and the questions to consider before any treatment decision.
Important considerations
The blend is not FDA-approved. Its ingredients, evidence, and risks should be reviewed for the specific formulation. Discuss the exact combination and alternatives with your clinician.
05 / PEPTIDE OPTIONS
Sermorelin
Sermorelin is a synthetic analogue of growth-hormone-releasing hormone. It remains one option within our broader peptide program, with the exact product, intended use, evidence, and risks reviewed during your consultation.
Important considerations
Compounded sermorelin is not FDA-approved. Historical approval of Geref does not establish approval of a compounded product or the effectiveness of adult anti-aging claims.
Learn About Sermorelin →
